SCHEMBL2264081

SCHEMBL2264081

COc1ccc2ncc(CC(N)=O)n2c1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
TGFBR1 P36897 3/20 0.40
CLK1 P49759 5/20 0.39
MEN1 O00255 1/20 0.39
MET P08581 1/20 0.38
GPR139 Q6DWJ6 1/20 0.37
MTNR1A P48039 2/20 0.37
MTNR1B P49286 2/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2265948 0.80 PRMT5 (0.42) PRMT5WDR77GPR139
SCHEMBL23108642 0.79 MET (0.42) PRMT5WDR77CLK1MEN1MET
SCHEMBL14290282 0.79 PRMT5 (0.41) PRMT5WDR77TGFBR1CLK1MEN1
SCHEMBL2262019 0.79 KDM4E (0.39) TGFBR1POLB
SCHEMBL2260901 0.78 POLB (0.56) PRMT5WDR77MEN1POLB
SCHEMBL2260330 0.78 ADORA2A (0.41) PRMT5WDR77TGFBR1
SCHEMBL2259799 0.78 POLB (0.37) TGFBR1CLK1POLB
SCHEMBL3607747 0.76 POLB (0.50) TGFBR1POLB
SCHEMBL23132918 0.75 CLK1 (0.40) PRMT5WDR77CLK1MEN1MET
SCHEMBL5768245 0.75 EIF2AK4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
EP-1483265-B1 PURINE DERIVATIVES AS KINASE INHIBITORS LILLY CO ELI (US) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PRMT5 809/4885WDR77 1243/4885TGFBR1 1303/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PRMT5 809/4885WDR77 1243/4885TGFBR1 1303/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 PRMT5 809/4885WDR77 1243/4885TGFBR1 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.